Literature DB >> 21220517

Nucleolar targeting of the fbw7 ubiquitin ligase by a pseudosubstrate and glycogen synthase kinase 3.

Markus Welcker1, Elizabeth A Larimore, Lori Frappier, Bruce E Clurman.   

Abstract

E3 ubiquitin ligases catalyze protein degradation by the ubiquitin-proteasome system, and their activity is tightly controlled. One level of regulation involves subcellular localization, and the Fbw7 tumor suppressor exemplifies this type of control. Fbw7 is the substrate-binding component of an SCF ubiquitin ligase that degrades critical oncoproteins. Alternative splicing produces three Fbw7 protein isoforms that occupy distinct compartments: Fbw7α is nucleoplasmic, Fbw7β is cytoplasmic, and Fbw7γ is nucleolar. We found that cancer-associated Fbw7 mutations that disrupt substrate binding prevent Fbw7γ nucleolar localization, implicating a substrate-like interaction in nucleolar targeting. We identified EBNA1-binding protein 2 (Ebp2) as the critical nucleolar factor that directly mediates Fbw7 nucleolar targeting. Ebp2 binds to Fbw7 like a substrate, and this is mediated by an Ebp2 degron that is phosphorylated by glycogen synthase kinase 3. However, despite these canonical substrate-like interactions, Fbw7 binding is largely uncoupled from Ebp2 turnover in vivo. Ebp2 thus acts like a pseudosubstrate that directly recruits Fbw7 to nucleoli.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21220517      PMCID: PMC3067902          DOI: 10.1128/MCB.01347-10

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  55 in total

Review 1.  Ubiquitin ligases: cell-cycle control and cancer.

Authors:  Keiichi I Nakayama; Keiko Nakayama
Journal:  Nat Rev Cancer       Date:  2006-05       Impact factor: 60.716

2.  Suprafacial orientation of the SCFCdc4 dimer accommodates multiple geometries for substrate ubiquitination.

Authors:  Xiaojing Tang; Stephen Orlicky; Zhenyuan Lin; Andrew Willems; Dante Neculai; Derek Ceccarelli; Frank Mercurio; Brian H Shilton; Frank Sicheri; Mike Tyers
Journal:  Cell       Date:  2007-06-15       Impact factor: 41.582

3.  The FBXW7 beta-form is suppressed in human glioma cells.

Authors:  Zhaodi Gu; Kenichi Inomata; Kota Ishizawa; Akira Horii
Journal:  Biochem Biophys Res Commun       Date:  2007-01-24       Impact factor: 3.575

4.  Expression of mouse Fbxw7 isoforms is regulated in a cell cycle- or p53-dependent manner.

Authors:  Akinobu Matsumoto; Ichiro Onoyama; Keiichi I Nakayama
Journal:  Biochem Biophys Res Commun       Date:  2006-09-12       Impact factor: 3.575

5.  Structure of a Fbw7-Skp1-cyclin E complex: multisite-phosphorylated substrate recognition by SCF ubiquitin ligases.

Authors:  Bing Hao; Stephanie Oehlmann; Mathew E Sowa; J Wade Harper; Nikola P Pavletich
Journal:  Mol Cell       Date:  2007-04-13       Impact factor: 17.970

6.  CDC4 mutations occur in a subset of colorectal cancers but are not predicted to cause loss of function and are not associated with chromosomal instability.

Authors:  Zoe Kemp; Andrew Rowan; William Chambers; Noel Wortham; Sarah Halford; Oliver Sieber; Neil Mortensen; Axel von Herbay; Thomas Gunther; Mohammad Ilyas; Ian Tomlinson
Journal:  Cancer Res       Date:  2005-12-15       Impact factor: 12.701

7.  The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling.

Authors:  Alena Malyukova; Takeaki Dohda; Natalie von der Lehr; Shahab Akhoondi; Shahab Akhondi; Martin Corcoran; Mats Heyman; Charles Spruck; Dan Grandér; Urban Lendahl; Olle Sangfelt
Journal:  Cancer Res       Date:  2007-06-15       Impact factor: 12.701

8.  Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers.

Authors:  Richard S Maser; Bhudipa Choudhury; Peter J Campbell; Bin Feng; Kwok-Kin Wong; Alexei Protopopov; Jennifer O'Neil; Alejandro Gutierrez; Elena Ivanova; Ilana Perna; Eric Lin; Vidya Mani; Shan Jiang; Kate McNamara; Sara Zaghlul; Sarah Edkins; Claire Stevens; Cameron Brennan; Eric S Martin; Ruprecht Wiedemeyer; Omar Kabbarah; Cristina Nogueira; Gavin Histen; Jon Aster; Marc Mansour; Veronique Duke; Letizia Foroni; Adele K Fielding; Anthony H Goldstone; Jacob M Rowe; Yaoqi A Wang; A Thomas Look; Michael R Stratton; Lynda Chin; P Andrew Futreal; Ronald A DePinho
Journal:  Nature       Date:  2007-05-21       Impact factor: 49.962

9.  The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia.

Authors:  Benjamin J Thompson; Silvia Buonamici; Maria Luisa Sulis; Teresa Palomero; Tomas Vilimas; Giuseppe Basso; Adolfo Ferrando; Iannis Aifantis
Journal:  J Exp Med       Date:  2007-07-23       Impact factor: 14.307

10.  FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors.

Authors:  Jennifer O'Neil; Jonathan Grim; Peter Strack; Sudhir Rao; Deanne Tibbitts; Christopher Winter; James Hardwick; Markus Welcker; Jules P Meijerink; Rob Pieters; Giulio Draetta; Rosalie Sears; Bruce E Clurman; A Thomas Look
Journal:  J Exp Med       Date:  2007-07-23       Impact factor: 14.307

View more
  18 in total

1.  Cullin 3 mediates SRC-3 ubiquitination and degradation to control the retinoic acid response.

Authors:  Christine Ferry; Samia Gaouar; Benoit Fischer; Marcel Boeglin; Nicodeme Paul; Eric Samarut; Aleksandr Piskunov; Gabriella Pankotai-Bodo; Laurent Brino; Cecile Rochette-Egly
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-06       Impact factor: 11.205

Review 2.  The two faces of FBW7 in cancer drug resistance.

Authors:  Zhiwei Wang; Hidefumi Fukushima; Daming Gao; Hiroyuki Inuzuka; Lixin Wan; Alan W Lau; Pengda Liu; Wenyi Wei
Journal:  Bioessays       Date:  2011-08-30       Impact factor: 4.345

3.  Glycogen Synthase Kinase 3 (GSK-3)-mediated Phosphorylation of Uracil N-Glycosylase 2 (UNG2) Facilitates the Repair of Floxuridine-induced DNA Lesions and Promotes Cell Survival.

Authors:  Carly A Baehr; Catherine J Huntoon; Song-My Hoang; Calvin R Jerde; Larry M Karnitz
Journal:  J Biol Chem       Date:  2016-11-14       Impact factor: 5.157

4.  SCF(Fbw7) modulates the NFkB signaling pathway by targeting NFkB2 for ubiquitination and destruction.

Authors:  Hidefumi Fukushima; Akinobu Matsumoto; Hiroyuki Inuzuka; Bo Zhai; Alan W Lau; Lixin Wan; Daming Gao; Shavali Shaik; Min Yuan; Steven P Gygi; Eijiro Jimi; John M Asara; Keiko Nakayama; Keiichi I Nakayama; Wenyi Wei
Journal:  Cell Rep       Date:  2012-05-31       Impact factor: 9.423

Review 5.  F-box proteins involved in cancer-associated drug resistance.

Authors:  Jian Gong; Yuqian Zhou; Deliang Liu; Jirong Huo
Journal:  Oncol Lett       Date:  2018-04-16       Impact factor: 2.967

6.  Distinct Interactions of EBP1 Isoforms with FBXW7 Elicits Different Functions in Cancer.

Authors:  Yuli Wang; Pengju Zhang; Yunshan Wang; Panpan Zhan; Chunyan Liu; Jian-Hua Mao; Guangwei Wei
Journal:  Cancer Res       Date:  2017-02-16       Impact factor: 12.701

7.  Fbw7α and Fbw7γ collaborate to shuttle cyclin E1 into the nucleolus for multiubiquitylation.

Authors:  Nimesh Bhaskaran; Frank van Drogen; Hwee-Fang Ng; Raman Kumar; Susanna Ekholm-Reed; Matthias Peter; Olle Sangfelt; Steven I Reed
Journal:  Mol Cell Biol       Date:  2012-10-29       Impact factor: 4.272

8.  A positive feedback loop between EBP2 and c-Myc regulates rDNA transcription, cell proliferation, and tumorigenesis.

Authors:  P Liao; W Wang; M Shen; W Pan; K Zhang; R Wang; T Chen; Y Chen; H Chen; P Wang
Journal:  Cell Death Dis       Date:  2014-01-30       Impact factor: 8.469

Review 9.  Targeting nucleocytoplasmic transport in cancer therapy.

Authors:  Richard Hill; Bastien Cautain; Nuria de Pedro; Wolfgang Link
Journal:  Oncotarget       Date:  2014-01-15

Review 10.  Aberrant regulation of FBW7 in cancer.

Authors:  Lixia Wang; Xiantao Ye; Yueyong Liu; Wenyi Wei; Zhiwei Wang
Journal:  Oncotarget       Date:  2014-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.